Create issue ticket



  • Ondansetron

    The oral rehydration solution consumption was significantly more in the ondansetron group (645 mL vs 554 mL; mean difference 91 mL; 95% CI: 35-148 mL).[] Safety Announcement Additional Information for Patients Additional Information for Healthcare Professionals Data Summary Safety Announcement [06-29-2012] The U.S.[] Precaution: Occasionally, ondansetron precipitates at the stopper/vial interface in vials stored upright. Potency and safety are not affected.[] Further Reading Thorpe PG, Gilboa SM, Hernandez-Diaz S, et al.[] 65862-0188-30 ONDANSETRON HCL TABLETS 30/BT 8MG Purchase Ondansetron HSI Manufacturer NDC Description Size Strength 1203737 AuroMedics 55150-0125-02 ONDANSETRON HCL INJ SDV[] Reprod Toxicol. 2014 Oct 24;50C:152-153. Colvin L, et al. 2013. Off-label use of ondansetron in pregnancy in Western Australia. Biomed Res Int. 2013:909860.[] Peak effect of intravenous ondansetron is 3 minutes. RESULTS: One hundred patients were included.[] Ondansetron area under the plasma concentration-time curve decreased progressively across gestation (634 ng hr/ml in early pregnancy, 553 ng hr/ml in mid-pregnancy, and 387[] Lahsaei SM, Amini A, Tabatabei SM, Mehrabani G. A comparison between cetirizine and ondansetron in preventing postoperative nausea and vomiting in adults.[] , imprinted with M, 734 007811679_PB round, white, imprinted with GG, 927 007811681_PB round, yellow, imprinted with GG, 928 551110153_PB round, white, imprinted with R, 153[]

  • Neostigmine

    KEEP OUT OF REACH OF CHILDREN REGISTRATION NUMBER: C 907 (Act 101/1965) 0,5 mg/mL Injection W/5.3/260 2,5 mg/mL Injection W/5.3/403 2,5 mg/mL Injection (5 mL vial) NAME AND[] In aqueous temperature-stressed solutions of neostigmine bromide besides the known product of hydrolysis additional degradation products were discovered, detected by TLC and[] McKesson 3664232 M&D 967240 42023-189-10 1 mg/mL 10 mL 10 mL 10 N Y ABC 10177621 Cardinal 5363122 McKesson 3664273 M&D 967281 PI Prescribing Information / SUV Single Use Vial / SDV[] High-dose neostigmine was associated with longer time to postanesthesia care unit discharge readiness (176 min [165 to 188] vs. 157 min [153 to 160]) and longer postoperative[] He developed asystole after intravenous administration of 4 mg neostigmine with 0.8 mg glycopyrrolate for reversal of the muscle relaxant.[] BACKGROUND: The addition of opioids to epidural local anesthetic reduces local anesthetic consumption by 20% but at the expense of side effects and time spent for regulatory[] Shnider SM, Levinson G: Anesthesia for Obstetrics. 3rd edition. Baltimore, Williams & Wilkins, 1993, p 275. James FM: Pharmacology of anesthetics.[] Low-dose neostigmine intravenously was used in the treatment of supraventricular tachycardia in three patients described herein.[] (both diluted with 1 ml normal saline).[] Thilen SR, Hansen BE, Ramaiah R, Kent CD, Treggiari MM, Bhanaker SM. Intraoperative neuromuscular monitoring site and residual paralysis.[]

  • Bortezomib

    (AUC last [SD]: 241 [82] ng·h/mL).[] Currently, VCD is considered as a primary regimen for patients with AL, but it is not clear whether the addition of cyclophosphamide to VD further and significantly improves[] Furthermore, it was stable for up to 8 days at 28  C in original vials with photoprotection.[] A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.[] , 2, 3 , Bennett MK 1, 2, 3 , Vandyke K 2, 3, 4 , Davies L 1, 2 , Zebol JR 1, 2 , Moretti PAB 1, 2 , Pitman MR 1, 2 , Hewett DR 3, 4 , Zannettino ACW 1, 2, 3, 4 , Pitson SM[] Overall response rates — which included partial response or better — were higher in the three-drug group (82%; n 176 of 216) compared with the two-drug group (72%; n 153 of[] In addition, autoantibodies directed against extractable nuclear antigens, such as anti-Sm, anti-RNP/Sm and anti-Ro/SSA, which are believed to be secreted by long-lived PCs[] Olujohungbe, Scott Marshall, Jane Conn, Heather Oakervee, Rakesh Popat and Jamie Cavenagh , Re‐transplantation after bortezomib‐based therapy , British Journal of Haematology , 153[] [email protected] (or) [email protected] Received date: September 30, 2016; Accepted date: October 12, 2016; Published date: October 15, 2016 Citation: Mehdad A, Freitas SM[] A second course of intravenous (IV) bortezomib resulted in a complete remission without evidence of relapse after 18 months.[]

    Missing: (SDV MDV OR
  • Ertapenem

    Ertapenem sodium salt, 100 mg/ml in distilled water, sterile-filtered MDL MFCD09475566 Chemical Properties Form Liquid Storage & Sensitivity Store at -20 C.[] In addition, 2 patients had recurrent infection at 6 months. Copyright 2014, American Society for Microbiology. All Rights Reserved.[] […] and/or alternatives Chemical Ingredient: Ertapenem Sodium Select Dosage: All 1g/Vial No generic is available for Invanz 1g/Vial.[] Shaikh S, Fatima J, Shakil S, Rizvi SM, Kamal MA. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment.[] PF LF Order Entry Number 42023-221-10 1 gm 15 mL N/A 10 Y Y ABC 10183232 Cardinal 5407861 McKesson 3740446 M&D 188417 PI Prescribing Information / SUV Single Use Vial / SDV[] Meropenem, biapenem, ertapenem, and doripenem are slightly more effective against Gram-negative organisms ( 11 , 153 , 181 ).[] SETTING/PRACTICE DESCRIPTION: A 71-year-old male was receiving intravenous antibiotics at an outside nursing facility through our Outpatient Parenteral Antimicrobial Therapy[] The patient's valproic acid serum concentration was 130 mug/ml approximately 3 months before he started ertapenem 2000 mg/day (20.6 mg/kg/day).[] O4O, VOP, PAP, GHP, HBV, AVC, PIC, SSS, SPF, VAF, NDP, YBF, SPD, VHC, SWA, NSL, AMH, MBP, ADM, RHW, PSF, DYL, IPP, WDE, SHC, FGH, JVN, NBG, MSD, RGH, NEW, WSI, UMP, GHC, SMS[] In addition, the effects were different in individual Enterobacteriaceae species. As a result, clinicians may opt to use alternative antimicrobial agents.[]

  • Plicamycin

    Specifications Safety and Handling Documents Specifications Specifications Chemical Name or Material Plicamycin CAS 18378-89-7 MDL Number MFCD00135618 Quantity 1mL Name Note 1mg/mL[] Four non-responders subsequently received additional chemotherapy and responded.[] Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.[] ---Ex. samarium SM 153 lexidronam, sodium iodide I 131, sodium phosphate P 32 -Leaking of an antineoplastic drug into surrounding tissues during IV administration.[] […] min/m2, and area under the plasma drug concentration-time curve of 1,289-1,546 ng-h/ml.[] We then treated eight additional patients in the blast phase of chronic granulocytic leukemia with a combination of alternate-day plicamycin and daily hydroxyurea.[] Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G, Alnemri ES.[] Cancer. 1983;51:149-153. 31. Tharapel SA, Plitman GI, Tharapel AT, Wilroy RS Jr.[] Following this, additional medication may be required approximately once a week.[] […] under refrigeration (2 C to 8 C); vials are stable at room temperature ( 5 W or NS is stable for 24 hours at room temperature.[]

    Missing: (SDV MDV OR
  • Posicor

    The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups.[] After 8 weeks of combined treatment, HCTZ was withdrawn and the mibefradil groups continued on their respective doses for an additional 6 weeks.[] Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.[] Sterile aerosol talc (Sclerosol) was approved for the prevention of recurrence of malignant pleural effusion, samarium Sm-153 lexidronam (Quadramet) was approved for the treatment[] […] most comprehensive databases of disclosed research in chemistry and related sciences, including the world's largest collection of substance information (the CAS REGISTRY SM[] […] roflumilast (Daliresp) romidepsin (Istodax) ropinirole (Requip, Requip XL, ReQuip Starter Pack, ReQuip Follow on Pack, Repreve, Requip Starter Kit) ropivacaine (Naropin, Naropin SDV[] Three mg of intravenous glucagon was administered, after which the patient experienced intense nausea and retching.[] Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg 1 mM 1.76 mL 8.79 mL 17.59 mL 5 mM 0.35 mL 1.76 mL 3.52 mL 10 mM 0.18 mL 0.88 mL 1.76 mL 50 mM 0.04 mL 0.18 mL 0.35 mL[] […] in DMSO, 53.4 mg/mL in EtOH with gentle warming, 96.8 mg/mL in H2O with gentle warming Storage Store at -20 C Shipping Condition Evaluation sample solution : ship with blue[] […] risky, so the FDA urged patients to call their doctors promptly about getting an alternative therapy--and until they get a new treatment, they should not begin taking any additional[]

    Missing: MDV OR
  • Human Herpesvirus 6

    […] copies/ml, respectively.[] Additional testing besides routine IFA is necessary for confirminig virus activity.[] Comparison of sensitivity for human cytomegalovirus of the polymerase chain reaction, traditional tube culture and shell vial assay by sequential dilutions of infected cell[] King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. ‎[] SDV and WCR contributed to data analysis and manuscript preparation. All authors commented on and approved the final draft. AL is the guarantor.[] MDV TMR mutants. Schematic representation of the MDV genome with a focus on viral a-like sequences containing the mTMR and sTMR regions present in the MDV genome.[] Am J Pathol 1998; 153 :175–182. 17. McCarthy KP , Sloane JP , Kabarowski JH , et al .[] The authors report the case of a 26-year-old man with subacute meningoradiculitis initially treated with intravenous immunoglobulin.[] Proper EA, Hoogland G, Kappen SM, Jansen GH, Rensen MG, et al. (2002) Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal[] One week after onset of intravenous antiviral therapy with foscarnet, disc edema subsided, and tonic pupil reaction was no longer detectable.[]

  • Doxorubicin

    Other Reverified 2/7/2014100 mg/mL, 10 mL (NDC 00517-7510-03)200 mg/mL, 4 mL (NDC 00517-7604-25)200 mg/mL, 10 mL (NDC 00517-7610-03)200 mg/mL, 30 mL (NDC 00517-7630-03)Fresenius[] However, frequent upregulation of anti-apoptotic pathways, chemotherapy-enhanced inflammation, and epithelial-mesenchymal transition (EMT), present additional aspects of cellular[] Kiyuna T 1 , Murakami T 2 , Tome Y 3 , Igarashi K 2 , Kawaguchi K 2 , Miyake K 2 , Miyake M 2 , Li Y 4 , Nelson SD 4 , Dry SM 4 , Singh AS 5 , Russell TA 6 , Singh SR 7 ,[] Cell 108 , 153–164 (2002) 3 Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K. & Donner, D. B.[] Vol. 30, Pg. 63, 1986. rabbit LD50 intravenous 5mg/kg (5mg/kg) Yiyao Gongye. Pharmaceutical Industry.[] Kiyuna T 1, 2, 3 , Tome Y 4 , Murakami T 1, 2 , Kawaguchi K 1, 2 , Igarashi K 1, 2 , Miyake K 1, 2 , Miyake M 1, 2 , Li Y 5 , Nelson SD 5 , Dry SM 5 , Singh AS 6 , Russell[] Kennedy Journal of Controlled Release 2011 153 (1), 4-15 Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery Anna Scomparin , Stefano Salmaso[] However, substance notifications in the InfoCard are aggregated independently of the impurities and additives.[] Cells were kept in Phenol Red-free DMEM medium with penicillin/streptomycin and 8% FCS.[] […] and that at 72 h of about 29 µg/mL.[]

  • Bone Metastasis

    For those who received primary ADT or surgery followed by ADT, CRPC was defined as one rising PSA value after a PSA nadir 4ng/ml, and confirmed by a second rising PSA value[] The purpose of this report was to identify the clinicopathological profiles of this rare clinical setting by evaluating 23 cases, four of which were our own and the additional[] (S)he also needs to check that the expiry date mentioned on the vial and on the package has not yet passed and that the selected vial is not damaged in any way.[] Other radiotherapies include Samarium-153 and Strontium-89, which are given intravenously (through a vein) to destroy the cancer cells in the bone in men with metastatic castration-resistant[] Kakonen SM, Mundy GR: Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003, 97:834–839. CrossRef PubMed Google Scholar 13.[] Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.[] BACKGROUND: Intravenous bisphosphonates (BPs) have been used to reduce the frequency of skeletal-related events due to bone metastases of several kinds of cancers.[] […] the patients without surgical treatment for bone metastasis was found to be 12 months (95% CI 5.89 - 18.10) and 42 months in patients who underwent surgical treatment in addition[] Examples of radiopharmaceuticals are Strontium-89, Samarium-153 and Radium-223.[] Scher , Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer , Journal of Clinical Oncology , 27 , 15 , (2436) , (2009[]

    Missing: (SDV MDV OR
  • Multiple Myeloma

    RESULTS: Median endocan concentration increased from MGUS (315.00 pg/ml) and healthy controls (316.19 pg/ml) to newly-diagnosed MM (371.82 pg/ml; p 0.027).[] In addition, recommendations cover monitoring, therapy duration, biochemical markers, and pain control.[] Leger JM, Viala K, Nicolas G, Creange A, Vallat JM, Pouget J, Clavelou P, Vial C, Steck A, Musset L, and Marin B.[] A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.[] Copyright 2006 by the American Society of Nephrology References Korbet SM, Schwartz MM: Multiple myeloma.[] Br J Haematol. 2011 Jun;153(6):721-8 Hillengass J, Fechtner K, Weber MA, Bäuerle T, Ayyaz S, Heiss C, Hielscher T, Moehler TM, Egerer G, Neben K, Ho AD, Kauczor HU, Delorme[] Prophylactic intravenous immune globulin (IVIG) reduces the incidence and recurrence of these infections in the stable phase of the disease.[] Correspondence: Giampaolo Merlini, Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Viale Golgi, 19 – 27100 Pavia, Italy; e-mail: gmerlini[] Loughrey GJ, Collins CD, Todd SM, Brown NM, Johnson RJ. MRI in the management of suspected spinal canal disease in patients with known malignancy.[] Cell 153 , 320–334 (2013). 56. Pichiorri, F. et al . MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis . Proc. Natl Acad. Sci.[]

    Missing: (SDV MDV OR

Similar symptoms